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Abstract
Background: Recently various lactic acid bacteria (LAB) and their post-metabolites have shown many positive effects on
human and animal welfare. They appear to be beneﬁcial in different disorders and pathological conditions, including in
a broad-spectrum of infectious diseases.
Aim: To estimate in vitro the anti-herpes simplex activity of 11 postbiotic samples (lysates or cell-free supernatants CFS) produced during the fermentation of six candidate-probiotic Lactobacillus strains isolated from Bulgarian fermented milk products.
Materials and methods: In vitro protocols for assessment of different LAB samples on the Herpes simplex virus type 1
(HSV-1) replication, adsorption and virucidal effects were applied using MDBK cells.
Results: Four of the studied LAB samples expressed a statistically signiﬁcant inhibition of the replication of HSV-1. The
highest selective index (79.75) was calculated for the post-metabolites of Lactiplantibacillus plantarum, followed by a
high molecular fraction of cell-derived fragments of Limosilactobacillus fermentum culture (S6) (SI ¼ 34.63), CFS from
late exponential L. plantarum (SI ¼ 28.26) and neutralized CFS from L. fermentum (SI ¼ 28.11). Pronounced virucidal
activities of the postbiotics S1, S11 (L. fermentum), S3 (L. plantarum) and S6 (L. fermentum) were recorded, too. The
inhibitory effect of the majority of the samples on the stage of adsorption of the virus to MDBK cells was remarkable. In
addition, almost all of the postbiotics exerted a protective effect on healthy cells and signiﬁcantly reduced viral yield at
subsequent infection.
Conclusion: Pre-selected Lactobacillus strains demonstrated strain-speciﬁc effects against HSV-1. These postbiotics
inﬂuence different stages of viral infection in cell cultures and their promising characteristics are currently evaluated.
Keywords: Antiviral activity, Herpes simplex virus type 1, Lactobacillus probiotics, Postbiotics

1. Introduction

H

erpes simplex virus type 1 (HSV-1) infection is
a widespread viral disease in the human
population with more than 90% of the individuals
being seropositive to the pathogen [1,2]. The virus is
transmitted via close contact with a carrier, whether
the person be asymptomatic or with the typical
manifestation. After a primary infection acquired
usually in the early childhood, the causative agent is
translocated through the peripheral sensory nerves
to the cranial nerve ganglion, where it establishes a
lifelong latent persistence [3]. When exposed to

different types of stimulation (temperature variation, prolonged exposure to sunlight, psychological
stress, physical overload, or other active contagious
diseases in the body, etc.), the latent virus can be
reactivated and cause a recurrent disease. Herpes
simplex virus (HSV) type 1 causes mainly symptoms
affecting the mouth, throat, lips, eyes and the central
nervous system but can also affect various areas of
the skin. Recently incidences of genital herpes
caused by HSV-1, as a result of transmission
through oral contact in this area, have been reported
[4e6]. Severe herpes-related conditions include encephalitis, meningitis, neonatal herpes [7,8], as well
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as disseminated infections in immunocompromised
patients have been described [9e11].
The speciﬁc anti-herpes chemotherapy relies on
nucleoside analogues which shorten the duration of
symptoms and lead to faster healing of lesions.
Currently, the most widely used drug is acyclovir
(ACV), which is also the ﬁrst selective inhibitor of
HSV developed [12,13]. A disadvantage of these
antivirals, both having been used as a ﬁrst line and
continuously applied medication in acute and
chronic cases, respectively, is the relatively rapid
formation of resistant mutants in patients with a
compromised immune system who are particularly
at risk. This naturally leads to the necessity to increase the therapeutic doses but unfortunately such
a treatment quite often inevitably fails [14e17].
Therefore, new therapeutics, other than those targeted by nucleoside analogues, are needed to be
enacted at different stages of the viral replication.
Products of natural origin are being considered as
possible candidates since they are better absorbed
and tolerated by cells and their therapeutic doses
are relatively low. Over the last few decades special
attention has been paid to probiotics and their
postmetabolites isolated from various dairy products [18]. Many of their biological activities, such as
antimicrobial, antifungal, anti-tumor, immunomodulatory and still many others, have been proven
[19]. Some probiotic postbiotics (the active metabolites produced during the fermentation) and/or
parabiotics (cell-derived fragments) have shown
antiviral activity. The postbiotics/parabiotics produced from live bacteria or released into environment after probiotic lysis may bring beneﬁcial
effects to the host [20]. These are presented by a
wide range of effector molecules such as short chain
fatty acids (SCFAs), bacteriocins, small molecules proteins/peptides, neurotransmitters, etc. [21] .
Bacteriocins produced by Lactobacillus delbrueckii
subsp. bulgaricus speciﬁcally inhibit the replication
of inﬂuenza virus A/chicken/Germany, strain
Weybridge (H7N7) and strain Rostock (H7N1) [22]. A
signiﬁcant decrease in inﬂuenza H1N1 virus titers
has also been observed in the treatment with
Lactobacillus plantarum L-137 of infected mice,
inducing a pro-inﬂammatory response [23]. When
administering Lactobacillus rhamnosus GG decreased
the incidence of respiratory viral infections [24] and
a reduction in inﬂuenza-like symptoms was recorded with Lactobacillus acidophilus strain NCFM [25].
Consistent and broad in vitro anti-HIV activity has
been reported for the carbocyclic lantibiotic Labyrinthopeptin A1 [26]. Glycerol monolaurate, a factor
analogously secreted by Lactobacillus, has virucidal
activity against enveloped viruses, including HIV-1
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[27]. Inhibitory activity against murine norovirus
(MNV) has also been investigated using a mixture of
metabolites of Lactilactobacillus curvatus 1 [28]. Exopolysaccharides produced by lactic acid bacteria
from genera Pediococcus, Leuconostoc and Lactobacillus show antiviral activity versus human Adenovirus type 5 [29]. Strains of L. plantarum and
Lactobacillus amylovorus exhibit good inhibitory effects against Echovirus 7 (E7) and E19 [30]. Biﬁdobacterium longum and L. plantarum in combination
with Chlorella soroquiniana in dairy products have
exerted anti-rotavirus activity [31]. However, limited
data exists on the mode of anti-Herpes simplex
virus
action
of
Lactobacillus-derived
postmetabolites/parabiotics. The lack of therapy capable
of eliminating herpes infections as well as the generation of resistant mutants in the current treatment
approach requires the development of new agents
with a mode of action alternative to nucleoside analogues. Having in mind the above stated objectives,
11 postbiotic samples obtained from 6 Lactobacillus
strains with probiotic properties were investigated
as anti-Herpes simplex virus type 1 agents at
different stages of replication.

2. Materials and methods
2.1. Lactobacilli and post-metabolites tested
Lactic acid bacteria (LAB) in the present study are
part of a laboratory collection of The Stephan
Angeloff Institute of Microbiology, Bulgaria. They
were pre-selected on the basis of previously estimated broad spectrum of anti-bacterial activity
[32,33]. All strains were stored at 20OC in MRS
broth, supplemented with glycerol (20% v/v). Prior to
the assay, all lactobacilli were pre-cultured twice in
MRS broth (Merck, Germany) at 37OC for 24e48 h.
A total of 11 samples (named S1eS11) (Table 1)
derived from 6 Lactobacillus strains and a multibacterial formula of 8 LAB strains were assessed for
anti-HSV activity. Two vaginal strains Limosilactobacillus fermentum (L.f. S3) and Ligilactobacillus salivarius (L.s. 1), four Lactiplantibacillus plantarum (L.pl.)
strains isolated from Bulgarian fermented milk
products such as home-made sample of a yogurtlike product “katak” [34] e L.pl. L3 and L14 and from
artisanal green cheese (produced only in the village
Tcherni vit, Bulgaria) e strains L. pl 3 ZS and 4 ZS
[33].
Four of the tested samples were ﬁltered acid cellfree supernatants (aCFS) from exponential (24 h)
cultures of the strains L. pl. L3 (sample S1); L. pl. L14
(S2), L. pl. ZS3 (S3) and L. pl. ZS4 (S4) in MRS broth
(Merck, Germany). The other samples were
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Table 1. LAB samples tested in the present work.
Samples

Tested strains

S1
S2
S3
S4
S5

L.
L.
L.
L.
L.

S6

L. fermentum S3

S7

Mixed LAB culture - Mix 8

S8

L. salivarius 1S

S9

L. fermentum S3

S10

L. fermentum S3

S11

L. fermentum S3

plantarum L3
plantarum L14
plantarum L3ZS
plantarum L4ZS
fermentum S3

Description of the samples
Acid CFS from exponential (24 h) cultures in MRS broth (Merck, Germany) at 37  C.

A low molecular mass fraction <30,000 Da obtained with centrifugation
(Hermle, Germany at 5000 rpm, 5 min) of aCFS from L. fermentum S3 culture in MRS,
using Amicone centrifuge tube, with cut-off membrane 30,000 Da.
A high molecular mass fraction >30,000 Da obtained with centrifugation (Hermle,
Germany at 5000 rpm, 5 min) of aCFS from L. fermentum S3 culture in MRS, using
Amicone centrifuge tube, with cut-off membrane 30,000 Da.
A supernatant obtained by centrifugation at 3000g from thermally destroyed
(15 min at 110  C) exponential mixed culture - Mix 8 (containing 8 Lactobacillus
strains cо-cultivated 24 h in MRS broth).
A supernatant, obtained by centrifugation at 3000g from ultra-sonicated
L. salivarius culture, cultivated 24 h in MRS broth at 37  C;
A neutralized cell-free supernatants (pH 6.0), with 5 M NaOH from a 24 h - culture
of L. fermentum S3 in MRS broth (pH 6.5);
A supernatant, obtained by centrifugation at 3000g from ultra- sonicated L. fermentum S3
culture, cultivated 24 h in MRS broth at 37  C
Filtered aCFS from exponential (24 h) cultures in MRS broth (Merck, Germany) at 37  C

different fractions from LAB postmetabolites in the
same laboratory medium as follows: the sample S5 a low molecular mass fraction <30,000 Da, obtained
with centrifugation (Hermle, Germany at 5000 rpm,
5 min) of a CFS of L. fermentum S3 culture, using
Amicone centrifuge tube, with cut-off membrane
30,000 Da; the sample S6 e a high molecular mass
fraction >30,000 Da, obtained as the S5 sample from
L. fermentum S3; sample S7 - the supernatant obtained by centrifugation at 3000g from thermally
destroyed (15 min at 110  C) exponential co-culture Mix 8 (containing 8 Lactobacillus strain cо-cultivated
24 h in MRS broth); the sample S8 e a supernatant,
obtained by centrifugation at 3000g from ultrasonicated L. salivarius 1 culture, cultivated 24 h in
MRS broth at 37  C; S9 e neutralized with 5 M
NaOH cell-free supernatants (pH 6.0) from a 24 h culture of L. fermentum S3- in MRS broth (pH 6.5);
the sample S10 - a supernatant, obtained by
centrifugation at 3000g from ultra-sonicated L.
fermentum S3 culture, cultivated 24 h in MRS broth at
37  C and the sample S11 e a CFS from 24 h L.
fermentum S3 culture in MRS broth. All samples
were ﬁlter sterilized (0.22 mm) and stored at 20  C
prior to the experiments.
The Bradford reagent (Sigma) with Coomassie
dye-binding assays was used for protein quantiﬁcation (mg/ml) of all samples, according to instructions of the manufacturer.
2.2. Virus and cells
MadineDarby bovine kidney (MDBK) cells were
obtained from National Bank for Industrial

Microorganisms and Cell Cultures, Soﬁa, Bulgaria.
The cell lines were grown in DMEM medium containing 10% v/v fetal bovine serum (Gibco BRL,
USA), supplemented with 10 mM HEPES buffer
(Merck, Germany) and antibiotics (penicillin 100 IU/
ml, streptomycin 100 mg/ml) in CO2 incubator
(HERA cell 150, Heraeus, Germany) at 37  C/5%
CO2.
Herpes simplex virus type 1, Victoria strain (HSV1) was received from Prof. S. Dundarov, National
Center of Infectious and Parasitic Diseases, Soﬁa.
Virus was replicated in monolayer MDBK cells in a
maintenance solution DMEM Gibco BRL, Paisley,
Scotland, UK, plus 0.5% fetal bovine serum Gibco
BRL, Scotland, UK. Infectious titer of stock virus was
107.5CCID50/ml.
2.3. Cytotoxicity of LAB samples
Conﬂuent monolayer cell culture in a 96-well
plates (Costar®, Corning Inc., Kennebunk, ME,
USA) was treated with 0.1 ml/well-containing a
maintenance medium containing no (untreated
control)/or decreasing concentrations of the tested
products. Cells were incubated at 37  C and 5% CO2
for 48 h. After microscopic evaluation, the medium
containing the test compound was removed; cells
were washed stained with neutral red and then
incubated at 37  C for 3 h. After the incubation, the
neutral red dye was removed; the cells were washed
with PBS, and 0.15 ml/well desorb solution (1%
glacial acetic acid and 49% ethanol in distilled
water) was added. The optical density (OD) of each
well was read at 540 nm in a microplate reader
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(Biotek Organon, West Chester, PA, USA). The 50%
cytotoxic concentration (CC50) was deﬁned as the
material concentration that reduced the cell viability
by 50% when compared to untreated control. Each
sample was tested in triplicate with four cell culture
wells per test sample.
The maximum tolerable concentration (MTC) of
the products, which is the concentration at which
they do not affect the cell monolayer and it looks
like the cells in the control (untreated with extract)
was also determined.
2.4. Antiviral activity
Cytopathic effect (CPE) inhibition test was used
for assessment of antiviral activity of the extracts.
Conﬂuent cell monolayer in 96-well plates infected
with 100-cell culture infectious dose 50% (CCID50) in
0.1 ml (HSV-1). After 60 min of virus adsorption,
each of the products was added in various concentrations and cells were incubated for 48 h at 37  C.
The cytopathic effect was determined using a
neutral red uptake assay and the percentage of CPE
inhibition for each concentration of the test sample
was calculated using the following formula:
% CPE ¼ [ODtest sample e ODvirus
control e ODvirus control]100

control]/[ODtoxicity

where ODtest sample is the mean value of the ODs of
the wells inoculated with virus and treated with the
test sample in the respective concentration, ODvirus
control is the mean value of the ODs of the virus
control wells (with no compound in the medium)
and ODtoxicity control is the mean value of the ODs of
the wells not inoculated with virus but treated with
the corresponding concentration of the test sample.
The 50% inhibitory concentration (IC50) was deﬁned
as the concentration of the material that inhibited
50% of viral replication when compared to the virus
control. The selectivity index (SI) was calculated
from the ratio CC50/IC50.
2.5. Virucidal assay
Contact samples of 1 ml containing HSV-1 (104
CCID50), as well as tested compound in its
maximum tolerable concentration in a 1:1 ratio was
stored at room temperature for different time intervals (15, 30, 60, 90 and 120 min). Then, the residual infectious virus content in each sample was
determined by the end-point dilution method and
Dlgs as compared to the untreated controls were
evaluated.

2.6. Virus attachment
Twenty four well cell culture plates containing
monolayer of MDBK cells were pre-chilled at 4  C
and were inoculated with 104 CCID50 of HSV-1 for
adsorption at 4  C and treated in parallel with MTC
of the extract. At various intervals (15, 30, 45 and
60 min) cells were washed with PBS in order to
remove both the compound and the unattached
virus, then overlaid with maintenance medium and
incubated at 37  C for 24 h. Following triple freezing
and thawing the infectious virus, titer of each sample was determined by the end-point dilution
method. Each sample was prepared in triplicate.
2.7. Pre-treatment of MDBK cells
Monolayers of MDBK cells pre-grown into 24-well
cell culture plates (CELLSTAR, Greiner Bio-One)
(2  106 cells per well) were treated for 15, 30, 60, 90
and 120 min at concentration of MTC of the extract
in the maintenance medium (1 ml per well). The
extract was then removed and the cells were washed
with phosphate-buffered saline (PBS) and inoculated with HSV-1 (1000 CCID50 in 1 ml per well).
After 60 min of absorption, the non-absorbed virus
was removed and the cells were covered with
maintenance medium. The culture plates were
incubated at 37  C for 24 h and, after triple freezing
and thawing, the infectious viral titers were determined by the end-point dilution method. Dlgs were
evaluated compared to viral control (untreated with
compounds).
Table 2. In vitro assessment of cytotoxicity and antiviral activity of LAB
post-metabolites.
Tested
samples

Cytotoxicity (mg/ml)

Antiviral activity

CC50

MTC

IC50 (mg/ml)

SI

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11
MRS broth
ACV

131.7 ± 5.34***
12.6 ± 1.54***
13.3 ± 0.54***
13.1 ± 1.85***
118.7 ± 3.98***
128.0 ± 3.43***
253.4 ± 8.21**
12.8 ± 2.12***
115.8 ± 4.24***
849.1 ± 5.32***
127.5 ± 6.64***
e
291.0 ± 9.4

2.1
0.6
2.0
0.6
6.6
1.8
12.3
0.6
1.9
120.0
6.3
157.1
e

0.8 ± 0.04***
1.85 ± 0.06***
3.07 ± 0.21***
0.23 ± 0.009**
e
2.05 ± 0.13***
e
e
1.0 ± 0.05***
10.0 ± 0.44***
6.22 ± 0.52***
e
0.33 ± 0.03

79.75
3.51
2.15
28.26
e
34.63
e
e
28.11
1.5
10.49
e
881.8

**p<0.001, when comparing the value of each post-metabolite
with ACV; Student's t-test.
***p<0.0001, when comparing the value of each post-metabolite
with ACV; Student's t-test.
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2.8. Statistical analyses

Table 3. Virucidal activity against HSV-1 various of LAB postmetabolites/parabiotics.

Determination of standard deviation (SD) was
done using the program Origin Pro 7.5. Student's ttest compared two groups of results. The ﬁnal data
sets were analyzed with the Graph Pad Prism 4
program.

Tested
samples

Dlg
15 min

30 min

60 min

90 min

120 min

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11

0.75
0
0.5
0.25
0
0.25
0.25
0
0.75
0.25
0.25

1.0
0
1.0
0.25
0
0.5
0.5
0.5
0.75
0.25
0.5

1.0
1.0
1.75
1.0
0.25
1.5
1.0
1.25
1.5
0.25
0.5

1.5
1.0
1.75
1.0
0.25
1.5
1.0
1.25
1.5
0.25
1.0

2.0
1.0
1.75
1.5
0.25
1.75
1.0
1.5
1.5
0.25
2.0

3. Results
The cytotoxicity assessment of the eleven LAB
samples (post-metabolites and cell-derived fragments) from 6 pre-selected Lactobacillus strains
(Table 1) was performed to exclude any possible
overlapping cytopathic effect of the samples and
changes induced purely by the virus itself. The
assay was performed on MDBK monolayer cell line
(Table 2).
One of the tested LAB (sample S8, which is
derived from 8 active strains) showed cytotoxicity
comparable to ACV and ﬁve LABs (samples S1, S5,
S6, S9 and S11) exhibited about two-fold higher
toxicity than the reference nucleoside analogue.
Four of the tested samples (S2, S3, S4 and S7) were
about 20 times more toxic than ACV and only one of
the products (S10) showed CC50 values which is
about 3 times higher than that of reference
substance.
In order to discard a probable effect of cytotoxicity
of the MRS medium used for LAB cultivation, we
also assessed its inﬂuence on the monolayer of
MDBK cells. The results showed no toxicity, even of
the stock solution (Table 2). The maximum tolerated
concentration of substances which does not induce
visible changes in the cell monolayer was also
determined.
The effect of LAB post-metabolites on viral replication in MDBK cells was evaluated, too (Table 2).
Four of the tested samples possessed remarkable
anti-herpesvirus activity. The highest selective
index (79.75) and therefore the most pronounced
effect on the internal replicative cycle of HSV-1 was
determined for aCFS of L. plantarum L3 (named S1
sample). Although being established as the most
potent among all the tested post-metabolites, its
effect was 10 times weaker than that of ACV. Next in
activity was sample S6 with a selective index of
34.63, followed by the aCFS of L. plantarum L4ZS (S4
sample) and neutralized CFS of L. fermentum S3
(named S9) with almost identical selective indices,
28.26 and 28.11, respectively. These results clearly
showed that an active metabolite different from
lactic acid is probably produced during the
fermentation. We observed weak anti-viral effect for
S11 (SI ¼ 10.49) and insigniﬁcant activities for S2

(SI ¼ 3.51), S3 (SI ¼ 2.15) and S10 (SI ¼ 1.5). Three
of the tested samples -S5, S7 and S8 did not show
any effect on the viral replicative cycle of HSV-1
(Table 2).
The pronounced activity of some of the post-metabolites against the intracellular replicative cycle of
HSV-1 inspired us to analyze whether they have an
effect on the extracellular virions of HSV-1. The
results in Table 3 indicate that at 15 min of virus
exposure none of the products shows any activity.
At 30 min exposure only S1 and S3 exert some
moderate activity, and S3 at 60 min exposure
showed Dlg ¼ 1.75, which is sustained until 120th
min (the last studied time interval) as compared to
virus control. Weak activity at 60 min was determined for S6, S7 and S9 with S7 and S9 showing no
greater virucidal properties up to 120th min, while
S6 at 120 min showed an activity of Dlg ¼ 1.75. The
strongest virucidal effect of all examined products
was recorded for S1 and S11 at 120 min with Dlg ¼ 2
compared to vehicle-treated group.
The effect of post-metabolites on the attachment
of HSV-1 virions to susceptible MDBK cells is
summarized in Table 4. At 15 min of exposure none
Table 4. Effect of LAB post-metabolites on viral adsorption of HSV-1 on
MDBK cells.
Tested
samples

Dlg
15 min

30 min

45 min

60 min

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11

1.25
0.25
0.25
0
0
0
0
0
0.25
0.25
0

4.75
1.5
1.5
1.25
0.25
1.75
1.25
0.5
2.0
0.5
1.75

4.75
1.5
1.5
1.25
0.25
3.0
3.0
2.5
2.0
1.25
3.0

5.0
2.0
1.75
1.25
0.5
5.5
5.0
5.0
2.0
1.75
5.5
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of the products showed any effect on the stage of
adsorption of the virus on the cell membrane. At the
next time interval of 30 min S1 exerted remarkable
activity of Dlg ¼ 4.75. Other products showing
virucidal activity at this time interval were S9
(Dlg ¼ 2.0), S6 (Dlg ¼ 1.75) and S11 (Dlg ¼ 1.75).
After 45 min of contact with the substances the most
impressive effect was calculated for S1 (Dlg ¼ 4.75),
S6, S8 and S11 (Dlg ¼ 3.0). S7 (Dlg ¼ 2.5) and S9
(Dlg ¼ 2.0). S2, S3 (Dlg ¼ 1.5) and S4, S10 (Dlg ¼ 1.25)
had low activity. At 60 min from the effect of the
post-metabolites a statistically strong inhibitory effect on the adsorption stage of HSV-1 virions to
sensitive MDBK cells was found for all tested
products except for S5 and S4.
The most signiﬁcant effect was demonstrated by
S6, S11 (Dlg ¼ 5.5) and S1, S7, S8 (Dlg ¼ 5.0). The
inﬂuence of S2, S9 (Dlg ¼ 2.0) and S3, S10
(Dlg ¼ 1.75) was also estimated as strong.
The protective effect of post-metabolites established on the stage of adsorption of viral particles to
host cells, brought us to the idea to test the samples’
behavior on uninfected MDBK cells when applied
prior to viral infection (Table 5). As early as 15 min
of incubation of the LAB samples with uninfected
cells the S9 (Dlg ¼ 2.5), S7 and S10 (Dlg ¼ 1.75)
signiﬁcantly preserved the cells from subsequent
herpes infections. At 30 min of treatment with probiotic post-metabolites all of them, except S5, exerted defensive effects to the cells. They varied for the
individual products: S9 (Dlg ¼ 2.5); S2, S11
(Dlg ¼ 2.25); S6 (Dlg ¼ 2.0); S1, S3, S8, S10
(Dlg ¼ 1.75) and a moderate effect was expressed by
S4, S7 (Dlg ¼ 1.5). It was enhanced by increasing the
exposure time and a clear protection was observed
after 120 min of treatment with the products (except
for S5, which did not show activity in any of the
studied time intervals). The most signiﬁcant were
the protective properties shown by acid CFS from L.

Table 5. Pretreatment of MDBK cells with LAB derived fragments or
postmetabolites before HSV-1 infection.
Tested
samples

Dlg
15 min

30 min

60 min

90 min

120 min

S1
S2
S3
S4
S5
S6
S7
S8
S9
S10
S11

1.0
0.5
0.25
0.25
0.25
0.5
1.5
1.75
2.5
1.75
0.5

1.75
2.25
1.75
1.5
0.25
2.0
1.5
1.75
2.5
1.75
2.25

2.0
2.25
1.75
2.0
0.25
2.25
1.5
2.0
2.5
1.75
2.25

2.5
2.5
2.0
2.25
0.5
2.75
2.0
2.75
2.5
2.0
2.5

3.5
3.0
2.0
3.5
0.5
3.5
2.0
3.25
3.0
2.0
3.0

plantarum strains in MRS - S1, S4 (Dlg ¼ 3.5); followed by a combination of 8 pre-selected candidate
probiotic strains - S8 (Dlg ¼ 3.25) and S2, S6, S11
(Dlg ¼ 3.0). Values for S3, S7, S10 samples were
evaluated as Dlg ¼ 2.0 (Table 5).

4. Discussion
One of the milestone challenges in developing
antiviral chemotherapeutic agents comes from the
natural conjunction between the viral replicative
mechanisms and the regular host cell processes.
Thus, targets for effective antiviral drugs are those
virus-speciﬁc structures and functions that determine viral replication but are not essential for the
cells and host organism's normal activities.
The ﬁrst stage that can be affected by any antiviral
candidate is the time before the pathogen enters the
cell, i.e. the studied samples act on extracellular virions. The reduction in the ability of virions to infect
sensitive cells is based on the capacity of particular
compounds to inactivate extracellular viral particles
nonspeciﬁcally by denaturating their proteins and/
or causing structural changes in supercapsid lipids.
Various mechanisms of action of probiotics in viral
infections exist but are not fully characterized.
Possibly the virucidal effect of the samples S1, S2, S3
and S4 reported in Table 3 is mainly due to the
detrimental effect of lactic acid produced during the
fermentation in the aCFS we studied. A similar effect has been described by the teams of Tuyama
et al., 2006 [35] and Conti et al., 2009 [36] against
human simplex virus type 2 (HSV -2). The presence
of such a non-speciﬁc interaction is also suggested
by the lack of a virucidal effect upon exposure to
neutralized CFS (in which lactic acid was eliminated
with NaOH). The probiotics may combat with
pathogens through different barrier mechanisms.
LABs appear to be a rich source of biologically active
products with diverse structure and biological
functions. This research suggests that the postmetabolites produced by selected Lactobacillus
strains during the fermentation in MRS broth are
able to inhibit HSV-1 infection of MDBK cells at
different stages of the replicative cycle. Thus,
different samples from acid and neutralized cellfree supernatants of exponential cultures in MRS
broth and cells fragments have been estimated. Our
hypothesis was that LAB are able to produce
different active metabolites during the fermentation,
able probably strain-speciﬁcally to inhibit virus
replication/attachment or infection. Moreover, it has
been shown that selected vaginal strains of Lactobacillus (Levilactobacillus brevis CD2, L. salivarius FV2,
L. plantarum FV9) as well as their cell-free

supernatants affect various steps of herpes simplex
virus type 2 (HSV-2) replication in vitro [36]. Independent studies on antiviral properties of multiple
probiotics and their derivatives on the replication of
herpes simplex viruses have been conducted [37]. It
has been shown that selected vaginal strains of
Lactobacillus, as well as their cell-free supernatants
affect various steps of herpes simplex virus type 2
(HSV-2) replication in vitro [36]. The bacterial extract
of Lactobacillus brevis and fragments of its cell wall
has demonstrated a dose-dependent inhibitory effect on HSV-2 proliferation [38].
Next, encouraged by the above-mentioned results, our questioning whether the probiotic samples can induce insusceptibility to viral infection by
pre-treatment of uninfected cells found its answer.
The obvious protective effect of the tested samples
on intact cells observed could be explained by their
bacteriocin content. Bacteriocin-like inhibitory substances (BLIS) can block the receptors on the host
cell responsible for virus recognition and binding
[39]. The defensive mechanism of pre-treatment of
cells with metabolic products of the probiotic L.
plantarum strain N4 against transmissible gastroenteritis Coronavirus has also been proven. The
analyzed composition of metabolic products by
GCeMS revealed that the major components were
sugars [40]. Perhaps the content and action of
similar constituents in the LAB samples we studied
explain the remarkable prophylactic antiviral properties on healthy cells of almost all tested samples,
especially S1, S2, S4, S6, S8, S9 and S11. They reduce
subsequent viral infection with a decrease in viral
titer by Dlg 3. Moreover, the effect was also signiﬁcant, after the elimination of protective role of
lactic acid produced, as it was shown for sample S9
containing nCFS. Concomitantly variants of produced post-metabolites (samples S5, S6, S9 and S11)
and parabiotics (S10) derived from the pre-selected
L. fermentum 3 S strain, were assessed for anti-HSV
effects in vitro.
Mousavi et al. (2018) assume that the inhibition of
the HSV-2 entry into cells occurs because viral
particles are trapped by Lactobacillus crispatus [41].
The same team suggested the formation of L. crispatus protective bioﬁlm on the cell surface that block
HSV-2 receptors and prevent the virus from
entering cells in the early stages of infection.
Intriguingly, our additional experiments with LAB
post-metabolites found potential of samples in
terms of inhibition of virus attachment and its subsequent entry and further infection-related events
(Table 4).
It has been suggested that bacteriocins secreted by
different strains of lactobacilli as positively charged
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compounds can be adsorbed on the viral capsid by
electrostatic interaction, thereby inhibiting viral
adsorption to the host cell [42]. The result of such an
interaction may be the inhibition of viral adsorption
reported by us, as well as the viral effect of some of
the samples. The L. fermentum S3 strain was preliminarily evaluated as a putative BLIS-producing
strain active against Gram (þ) and Gram () bacteria (unpublished data). Therefore, we prepared
different samples to visualize the activity of the
obtained postbiotics - low molecular weight samples
- S5 or >30,000 Da e S6 and cells-free supernatants
of spent cultures -S9 and S11). Thermal destructed
cells from exponential culture of L. salivarius 1 S e
the sample S8, shows a complete absence of antiviral activity, despite the previously proven bacteriocinogenic anti-Salmonella activity [33]. Probably
the active proteinaceous compound produced by L.
salivarius 1 S was completely destroyed by high
temperature (120  C).
Herpes viruses induce the expression of a large
number of virus-speciﬁc enzymes in the infected
cells. They mimic the action of functionally related
cellular enzymes but differ in a number of
biochemical characteristics such as molecular
weight, dependence on certain cations, sensitivity to
inhibitors, substrate speciﬁcity and many others.
The most effective therapeutics are those that block
the intracellular replicative cycle of the virus by
attacking speciﬁc viral structures in the infected cell
that are necessary for its reproduction.
In this study, the highest selective indices were
calculated for samples S1, S4, S6, S9 and S11, which
could indicate interruption in one or more important steps of the intracellular replication cycle of
HSV-1. This effect is not likely solely as a result of
the lactic acid content present in the samples.
Sample S9 was also active lacking lactic acid by
neutralization in CFS of the exponential culture of
one candidate probiotic strain Lf. S3 (Table 2). Serkedzhieva et al. (2000) found that bacteriocin B1
from Lactobacillus delbrueckii inhibited certain stages
of the intracellular replicative cycle of the virus [22].
Wachsman et al. (2003) show that inhibition of HSV
replication by enterocin CRL35 occurs in the late
stages of virus replication by preventing the synthesis of gamma protein-glycoprotein D (gD), a
structural component of the HSV envelope that is
essential for entry of the virus in the host cell [39]. In
other studies, a non-protein component contained
in the cell wall of Lactobacillus brevis also has the
ability to reduce HSV-2 replication [38]. Our assays
in accordance with other teams, prove an inhibitory
effect on viral particles and viral replication of LAB
and
their
postmetabolites.
However,
the
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experiments conducted so far represent only the
initial stage of this research. It is necessary further to
establish in more details the exact chemical
composition of postmetabolites, as well as the effect
that each ingredient has on viral replicative cycle.
Additional studies should be performed to determine the precise mechanism explaining the antiherpes effect observed in the studies.

5. Conclusion
All in all, tested Lactobacillus strains demonstrated
a strain-speciﬁc effect against HSV-1. This study
assesed the capacity of LABs postmetabolites/cellderived fragments to inﬂuence different stages of
viral infection in cell cultures. Our in vitro achievements showed new aspects for widespread use of
LABs and their postbiotics in the treatment of herpes infections. They could successfully shorten and
limit existing herpes recurrence, disrupting both
stages of virus replication and restricting the
movement and passage of the virus from cell to cell.
The protective effect they have on healthy cells is
also extremely important protecting them to a signiﬁcant extent from the entry of viral particles into
them. These activities would make LABs and their
post metabolites reliable future therapies for herpes
infections. Despite the reported decrease in viral
yield at different stages of viral cycle, the exact
mechanism by which probiotics and their post-metabolites act has not been established so far. This
opens a broad perspective in the development and
application of probiotics as antiviral agents with a
variety of additional biological activities and beneﬁts for human health.
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